CY1121980T1 - Αντισωματα anti-cd26 και χρησεις εξ αυτων - Google Patents
Αντισωματα anti-cd26 και χρησεις εξ αυτωνInfo
- Publication number
- CY1121980T1 CY1121980T1 CY20191100774T CY191100774T CY1121980T1 CY 1121980 T1 CY1121980 T1 CY 1121980T1 CY 20191100774 T CY20191100774 T CY 20191100774T CY 191100774 T CY191100774 T CY 191100774T CY 1121980 T1 CY1121980 T1 CY 1121980T1
- Authority
- CY
- Cyprus
- Prior art keywords
- present
- provides
- treatment
- antibodies
- gvhd
- Prior art date
Links
- 208000009329 Graft vs Host Disease Diseases 0.000 abstract 2
- 208000024908 graft versus host disease Diseases 0.000 abstract 2
- 208000032467 Aplastic anaemia Diseases 0.000 abstract 1
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 abstract 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001737 promoting effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fats And Perfumes (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε καινοφανή αντισώματα δυνάμενα δέσμευσης σε CD26, ως επίσης και στη χρήση αυτών ως ένα φάρμακο. Εξάλλου, η παρούσα εφεύρεση παρέχει αντισώματα για χρήση σε αγωγή και/ή πρόληψη Πάθησης Μοσχεύματος-έναντι-Ξενιστή (GvHD), για χρήση σε αγωγή Απλαστικής Αναιμίας και/ή για χρήση σε προαγωγή εμμόσχευσης μετά από μεταμόσχευση αιμοποιητικών αρχέγονων κυττάρων. Προσέτι, η παρούσα εφεύρεση παρέχει φαρμακευτικές συνθέσεις περιλαμβάνοντας τουλάχιστον ένα αντίσωμα της παρούσας εφεύρεσης, καθώς παρέχει επίσης ένα κιτ από μέρη.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13425029.9A EP2767549A1 (en) | 2013-02-19 | 2013-02-19 | Anti-CD26 antibodies and uses thereof |
| EP14705767.3A EP2864359B1 (en) | 2013-02-19 | 2014-02-19 | Anti-cd26 antibodies and uses thereof |
| PCT/EP2014/053243 WO2014128168A1 (en) | 2013-02-19 | 2014-02-19 | Anti-cd26 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1121980T1 true CY1121980T1 (el) | 2020-10-14 |
Family
ID=48092884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100774T CY1121980T1 (el) | 2013-02-19 | 2019-07-22 | Αντισωματα anti-cd26 και χρησεις εξ αυτων |
Country Status (26)
| Country | Link |
|---|---|
| US (2) | US9376498B2 (el) |
| EP (3) | EP2767549A1 (el) |
| JP (2) | JP6240195B2 (el) |
| KR (1) | KR101869589B1 (el) |
| CN (1) | CN104684931B (el) |
| AU (1) | AU2014220777B2 (el) |
| CA (1) | CA2874422C (el) |
| CY (1) | CY1121980T1 (el) |
| DK (1) | DK2864359T3 (el) |
| ES (1) | ES2738283T3 (el) |
| HK (1) | HK1205151A1 (el) |
| HR (1) | HRP20191277T8 (el) |
| HU (1) | HUE045150T2 (el) |
| IL (1) | IL237244B (el) |
| LT (1) | LT2864359T (el) |
| ME (1) | ME03753B (el) |
| MX (1) | MX357293B (el) |
| NZ (1) | NZ631111A (el) |
| PL (1) | PL2864359T3 (el) |
| PT (1) | PT2864359T (el) |
| RS (1) | RS59093B1 (el) |
| RU (1) | RU2662933C2 (el) |
| SA (1) | SA515360248B1 (el) |
| SI (1) | SI2864359T1 (el) |
| TR (1) | TR201910572T4 (el) |
| WO (1) | WO2014128168A1 (el) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11242399B2 (en) * | 2013-02-19 | 2022-02-08 | Adienne S.A. | Anti-CD26 antibodies |
| EP2767549A1 (en) * | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
| US10630229B2 (en) * | 2016-10-11 | 2020-04-21 | Kevin Stapleton | Panel mounting bracket with grounding mid-clamp and related methods |
| KR101960414B1 (ko) * | 2016-11-11 | 2019-03-27 | 대한민국 | 사람 유래 dpp-4 유전자를 이용한 당뇨 질환 모델용 형질전환돼지 및 이의 용도 |
| EP3729085A1 (en) | 2017-12-22 | 2020-10-28 | Adienne S.A. | Quantitative cellular method for determining the biological activity of an anti-cd26 ligand |
| CN109709337B (zh) * | 2018-12-28 | 2021-09-14 | 江苏众红生物工程创药研究院有限公司 | 人cd26的免疫组化检测试剂盒及其临床应用 |
| CA3187315A1 (en) * | 2020-07-28 | 2022-02-03 | Antonio Francesco Di Naro | Treatment of idiopathic inflammatory myopathies |
| MX2023012636A (es) * | 2021-05-13 | 2023-11-08 | Adienne S A | Metodos de tratamiento de la dermatomiositis. |
| BR112023022724A2 (pt) * | 2021-05-13 | 2024-02-20 | Adienne S A | Métodos de tratamento da doença do enxerto contra o hospedeiro |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4704692A (en) | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| ATE207080T1 (de) | 1991-11-25 | 2001-11-15 | Enzon Inc | Multivalente antigen-bindende proteine |
| NL9400309A (nl) * | 1993-11-04 | 1995-06-01 | Eurogenetics Nv | Ligande die in staat is te binden aan de adenosine deaminase bindingsplaats van CD26. |
| PT1241179E (pt) | 1998-04-15 | 2006-12-29 | Genentech Inc | Proteína humana possuindo actividade antiproliferativa in vitro |
| EP1197755A1 (en) | 2000-10-11 | 2002-04-17 | Pepscan Systems B.V. | Identification of protein binding sites |
| CN101172158A (zh) * | 2001-05-11 | 2008-05-07 | 得克萨斯州立大学董事会 | 抗cd26单克隆抗体作为对与表达cd26的细胞相关疾病的治疗 |
| US7863239B2 (en) | 2005-01-24 | 2011-01-04 | Pepscan Systems B.V. | Binding compounds, immunogenic compounds and peptidomimetics |
| ES2665422T3 (es) | 2005-03-03 | 2018-04-25 | Immunomedics Inc. | Anticuerpos L243 humanizados |
| WO2007014169A2 (en) | 2005-07-22 | 2007-02-01 | Y's Therapeutics Co, Ltd. | Anti-cd26 antibodies and methods of use thereof |
| CN102908350B (zh) * | 2005-09-14 | 2014-07-23 | 武田药品工业株式会社 | 用于治疗糖尿病的二肽基肽酶抑制剂 |
| US8846393B2 (en) * | 2005-11-29 | 2014-09-30 | Gamida-Cell Ltd. | Methods of improving stem cell homing and engraftment |
| RU2331881C1 (ru) * | 2007-03-09 | 2008-08-20 | ГОУ ВПО "Красноярская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" | Способ определения риска развития атопических заболеваний у новорожденных детей |
| BRPI0919473A2 (pt) | 2008-09-26 | 2017-08-29 | Oncomed Pharm Inc | Agentes de ligação frizzled e usos dos mesmos |
| EP3530274A1 (en) * | 2010-08-18 | 2019-08-28 | Theresa Deisher | Dexamethasone to reduce stem cell accumulation in the spleen |
| EP2767549A1 (en) * | 2013-02-19 | 2014-08-20 | Adienne S.A. | Anti-CD26 antibodies and uses thereof |
-
2013
- 2013-02-19 EP EP13425029.9A patent/EP2767549A1/en not_active Withdrawn
-
2014
- 2014-02-19 RU RU2014153440A patent/RU2662933C2/ru active
- 2014-02-19 DK DK14705767.3T patent/DK2864359T3/da active
- 2014-02-19 PT PT14705767T patent/PT2864359T/pt unknown
- 2014-02-19 CN CN201480002117.1A patent/CN104684931B/zh active Active
- 2014-02-19 NZ NZ631111A patent/NZ631111A/en unknown
- 2014-02-19 SI SI201431259T patent/SI2864359T1/sl unknown
- 2014-02-19 AU AU2014220777A patent/AU2014220777B2/en active Active
- 2014-02-19 HU HUE14705767A patent/HUE045150T2/hu unknown
- 2014-02-19 LT LTEP14705767.3T patent/LT2864359T/lt unknown
- 2014-02-19 KR KR1020147035708A patent/KR101869589B1/ko active IP Right Grant
- 2014-02-19 ES ES14705767T patent/ES2738283T3/es active Active
- 2014-02-19 TR TR2019/10572T patent/TR201910572T4/tr unknown
- 2014-02-19 JP JP2015529076A patent/JP6240195B2/ja active Active
- 2014-02-19 RS RS20190938A patent/RS59093B1/sr unknown
- 2014-02-19 PL PL14705767T patent/PL2864359T3/pl unknown
- 2014-02-19 ME MEP-2019-212A patent/ME03753B/me unknown
- 2014-02-19 EP EP14705767.3A patent/EP2864359B1/en active Active
- 2014-02-19 CA CA2874422A patent/CA2874422C/en active Active
- 2014-02-19 EP EP19170670.4A patent/EP3536711A1/en not_active Withdrawn
- 2014-02-19 US US14/184,241 patent/US9376498B2/en active Active
- 2014-02-19 MX MX2014014935A patent/MX357293B/es active IP Right Grant
- 2014-02-19 WO PCT/EP2014/053243 patent/WO2014128168A1/en active Application Filing
-
2015
- 2015-02-16 IL IL237244A patent/IL237244B/en active IP Right Grant
- 2015-04-07 SA SA515360248A patent/SA515360248B1/ar unknown
- 2015-06-18 HK HK15105797.7A patent/HK1205151A1/xx unknown
-
2016
- 2016-05-31 US US15/169,386 patent/US10208126B2/en active Active
-
2017
- 2017-07-10 JP JP2017134896A patent/JP2017221205A/ja active Pending
-
2019
- 2019-07-17 HR HRP20191277T patent/HRP20191277T8/hr unknown
- 2019-07-22 CY CY20191100774T patent/CY1121980T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1121980T1 (el) | Αντισωματα anti-cd26 και χρησεις εξ αυτων | |
| CY1122278T1 (el) | Αντι il-36r αντισωματα | |
| MX2019006362A (es) | Una combinacion de inmunoconjugado y anticuerpo para usarse en el tratamiento de cancer. | |
| EA202193044A2 (ru) | Способы лечения таупатии | |
| UA117072C2 (uk) | Cd3-зв'язувальна молекула, здатна до зв'язування з cd3 людини, і cd3, що не є людським | |
| EA201491811A1 (ru) | АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ | |
| EA201692301A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201691988A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201690667A1 (ru) | Композиции, содержащие антитело к pdl1 | |
| EA201492216A1 (ru) | Ингибиторы бромодомена и их применение | |
| EA201992133A1 (ru) | Производные пиперидино-пиримидина для лечения вирусных инфекций | |
| EA201391719A1 (ru) | Хиназолиновые производные для лечения вирусных инфекций и дальнейших заболеваний | |
| EA201591166A1 (ru) | Ингибиторы аутотаксина | |
| EA201590855A1 (ru) | Соединения пирролопиримидина как ингибиторы киназ | |
| EA201791186A1 (ru) | Антитела к cd38 | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| EA201201357A1 (ru) | Антитела к cd40 | |
| EA201390682A1 (ru) | Спирооксиндольные антагонисты mdm2 | |
| EA201491947A1 (ru) | Антитела и иммуноконъюгаты к ly6e и способы применения | |
| BR112014031310A2 (pt) | anticorpos anti-pcsk9, formulações, dosagem e métodos de uso | |
| EA201201016A1 (ru) | Антидоты антикоагулянтов | |
| UA118332C2 (uk) | Білок, що зв'язує антиген cd27l | |
| EA201590731A1 (ru) | Антитела к гемагглютинину и способы применения | |
| AR090923A1 (es) | Anticuerpos anti-il-23 | |
| EA201400976A1 (ru) | Бензодиоксаны в комбинации с другими активными средствами для ингибирования продуцирования лейкотриена |